- Lobe Sciences (LOBE) to present at the Benzinga Global Small Cap Conference
- Philip Young, CEO and Director will be presenting on Thursday, May 13 at 12:25 pm ET
- The Benzinga Global Small Cap Conference bridges the gap between Small Cap companies, investors, and traders
- Lobe is a life sciences company focused on psychedelic medicines
- Lobe Sciences Ltd. (LOBE) is down 4 per cent and is trading at C$0.12 at 1:59 pm ET
Lobe Sciences Ltd. (LOBE) will be presenting at the Benzinga Global Small-Cap Conference taking place on May 13-14, 2021.
Philip Young, CEO and Director will be presenting on Thursday, May 13 at 12:25 pm ET.
Philip Young, CEO and Director of Lobe, stated,
“We look forward to discussing the latest developments and opportunities ahead of us as we continue on our mission to improve the health of people globally by improving the human condition.”
To find out more information and/or to register for a free spectator pass for the conference, Lobe suggests heading to Benzinga’s website.
The Benzinga Global Small Cap Conference bridges the gap between Small Cap companies, investors, and traders.
It also suggests–if interested in learning more about small cap investing with clearly defined educational modules–to look at a curated group of smallcap investment opportunities and connect with the global small cap audience in an intimate, virtual setting.
Lobe is a life sciences company focused on psychedelic medicines.
Lobe, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.
Lobe Sciences Ltd. (LOBE) is down 4 per cent and is trading at C$0.12 at 1:59 pm ET.
